CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma

NCT07340853 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma
Recurrent Multiple Myeloma
Refractory Multiple Myeloma

Interventions

PROCEDURE: Leukapheresis
DRUG: Cyclophosphamide
BIOLOGICAL: Chimeric Antigen Receptor T cells (CAR-T) Targeting BCMA
BEHAVIORAL: Quality of Life (QoL) Questionnaires
PROCEDURE: Bone Marrow Biopsy
BIOLOGICAL: Biospecimen Collection
DRUG: Fludarabine
PROCEDURE: Radiographic imaging

Sponsor

Thomas Martin, MD